Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

Fig. 1

Trough FEV1 (mL) change from baseline during the 1-year treatment period (a) for the overall study population and (b) in subgroups of patients with or without concurrent use of LABA (LS mean change from baseline; ITT population). FEV1, forced expiratory volume in 1 s; ITT, intent-to-treat; LABA, long-acting β-agonist; LS, least squares; REV, revefenacin; SE, standard error; TIO, tiotropium

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us